Alzheimer Disease Clinical Trial
— InveCeAbOfficial title:
A Longitudinal Population Study on Brain Aging and Mental Performances for the 1935-1939 Born People Living in Abbiategrasso (a Small Town Near Milan)
Verified date | December 2015 |
Source | Fondazione Golgi Cenci |
Contact | n/a |
Is FDA regulated | No |
Health authority | Italy: Ethics Committee |
Study type | Observational |
Longitudinal observational study of cognitive functions, physical health and biological
parameters in the whole population living in Abbiategrasso born between 1935 and 1939,1773
subjects, followed for six years in order to know the prevalence and the incidence of
dementia and risk and protective factors of normal and pathological mental aging.
The peculiarities of this study that must assure the outcome efficacy are:
- Selected age: since 70-75 years old people represents a transition age from adulthood
to old age, it is of special interest to study the evolution of psychic and physical
functions of this population
- Whole population not a sample study
- Location: the small area involved (Abbiategrasso is a town of 30.000 inhabitants)can
contribute to guarantee more homogeneity among the subjects and reduce undesired
variability
- multidimensional assessment(biological, clinical, social, psychological data collected)
After initial screening, the recruited population will be followed up for two more
times (every two years )
Status | Completed |
Enrollment | 1321 |
Est. completion date | December 2015 |
Est. primary completion date | December 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 70 Years to 75 Years |
Eligibility |
Inclusion Criteria: - to be resident in Abbiategrasso - to be born between 1935 and 1939 Exclusion Criteria: - to refuse to participate - te be not contactable in any way (mail, telephone) - to be legally resident, but actually living somewhere else |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Italy | Golgi Cenci Foundation | Abbiategrasso | Milan |
Lead Sponsor | Collaborator |
---|---|
Fondazione Golgi Cenci | Federazione Alzheimer Italia, Milan (Italy), Geriatric Institute Camillo Golgi, Abbiategrasso, Milan (Italy), Mario Negri Institute for Pharmacological Research, University of Pavia |
Italy,
Guaita A, Colombo M, Vaccaro R, Fossi S, Vitali SF, Forloni G, Polito L, Davin A, Ferretti VV, Villani S. Brain aging and dementia during the transition from late adulthood to old age: design and methodology of the "Invece.Ab" population-based study. BMC Geriatr. 2013 Sep 24;13:98. doi: 10.1186/1471-2318-13-98. — View Citation
Guaita A, Forloni GL, Ferretti V, Villani S, Fossi S, Colombo M, Salvini Porro G InveCe.Ab: a multidimensional population study on brain aging for the 1935 - 1939 born people in a small town near Milan JNHA ( the Journal of Nutrition, Health &Aging) 2010; 14 (supplement 2): S17
Guaita A, Vaccaro R, Davin A, Colombo M, Vitali SF, Polito L, Abbondanza S, Valle E, Forloni G, Ferretti VV, Villani S. Influence of socio-demographic features and apolipoprotein E epsilon 4 expression on the prevalence of dementia and cognitive impairment in a population of 70-74-year olds: the InveCe.Ab study. Arch Gerontol Geriatr. 2015 Mar-Apr;60(2):334-43. doi: 10.1016/j.archger.2014.11.006. Epub 2014 Nov 25. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The proportion of the recruited persons who will develop Dementia syndrome, Alzheimer disease, Vascular dementia, Lewy Body dementia, frontotemporal dementia, Mild Cognitive Impairment, Cognitive Impairment No Dementia | These are the criteria used for the definitions : DSM IV for Dementia syndrome NINCDS ADRDA diagnostic criteria for Alzheimer disease NINDS -AIREN criteria for Vascular dementia Third report, DLB consortium for Lewy Body dementia 2002 modified Consensus Conference criteria for frontotemporal dementia Report of the MCI Working Group of the European Consortium on Alzheimer's Disease for Mild Cognitive Impairment (MCI) Absence of the first criteria for MCI (subjective complain) for the definition of Cognitive Impairment No Dementia (CIND) |
six years | No |
Secondary | The proportion of persons who will exhibit a performance decrease equal or more than of 1,5 standard deviation of the mean in the reference population in screening cognitive tests or in memory tests (verbal and visual memory) or in executive tests | Screening cognitive tests: Clock test and MMSE. Memory tests: Babcock Story Recall Test , Rey 15-item Memory Test, and the Rey-Osterrieth Complex Figure Test (ROCF) recall. Executive tests:Trial making A and B; copy of ROCF |
six years | No |
Secondary | Neuropsychological baseline features of the persons who will develop dementia or cognitive impairment | Mood: GDS 15 items Verbal and visual memory: Babcock Story Recall Test, Rey 15-item Memory Test, and the Rey-Osterrieth Complex Figure Test (ROCF) recall Executive function: TMTA and TMTB; copy of ROCF Attention: Numerical Attention Abstract reasoning: Raven's Coloured Progressive Matrices Screening cognitive test: Clock test and MMSE |
six years | No |
Secondary | Clinical baseline features of the persons who will develop dementia or cognitive impairment | Index of co morbidities as defined by CIRS (Cumulative Index Rating Scale) Standard neurological examination |
six years | No |
Secondary | Social baseline features of the persons who will developed dementia or cognitive impairment | Stressful life events as defined in GALES (Geriatric Adverse Life Event Scale) Physical activity Social network |
six years | No |
Secondary | Genetic baseline features of the persons who will developed dementia and/or cognitive impairment | ApoE Inflammatory cytokines |
six years | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04079803 -
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
|
Phase 2 | |
Completed |
NCT04044495 -
Sleep, Rhythms and Risk of Alzheimer's Disease
|
N/A | |
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Recruiting |
NCT04520698 -
Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease
|
N/A | |
Active, not recruiting |
NCT04606420 -
Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05820919 -
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
|
N/A | |
Terminated |
NCT03672474 -
REGEnLIFE RGn530 - Feasibility Pilot
|
N/A | |
Completed |
NCT03430648 -
Is Tau Protein Linked to Mobility Function?
|
||
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Recruiting |
NCT04949750 -
Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05288842 -
Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
|
||
Recruiting |
NCT05557409 -
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
|
Phase 3 | |
Completed |
NCT06194552 -
A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07
|
Phase 1 | |
Completed |
NCT03239561 -
Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
|
Early Phase 1 | |
Completed |
NCT03184467 -
Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Terminated |
NCT03487380 -
Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease
|
N/A | |
Completed |
NCT05538455 -
Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases
|
N/A | |
Recruiting |
NCT05328115 -
A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease
|
Phase 1 | |
Completed |
NCT05562583 -
SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support
|
N/A |